LeMaitre Vascular (NASDAQ:LMAT) CEO George Lemaitre Sells 18,600 Shares

LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO George Lemaitre sold 18,600 shares of LeMaitre Vascular stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $107.64, for a total transaction of $2,002,104.00. Following the sale, the chief executive officer directly owned 1,457,900 shares in the company, valued at $156,928,356. The trade was a 1.26% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

LeMaitre Vascular Trading Down 5.8%

Shares of LMAT traded down $6.30 during trading hours on Monday, reaching $101.64. 410,363 shares of the company traded hands, compared to its average volume of 209,885. The company’s fifty day moving average price is $110.00 and its two-hundred day moving average price is $94.48. The company has a market capitalization of $2.32 billion, a price-to-earnings ratio of 37.51, a price-to-earnings-growth ratio of 3.00 and a beta of 0.60. The company has a quick ratio of 12.20, a current ratio of 14.32 and a debt-to-equity ratio of 0.42. LeMaitre Vascular, Inc. has a 12 month low of $78.35 and a 12 month high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.66 by $0.02. The firm had revenue of $66.55 million for the quarter, compared to analyst estimates of $66.67 million. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The company’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.48 EPS. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Equities research analysts predict that LeMaitre Vascular, Inc. will post 3 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Thursday, May 21st will be paid a dividend of $0.25 per share. The ex-dividend date of this dividend is Thursday, May 21st. This represents a $1.00 annualized dividend and a yield of 1.0%. LeMaitre Vascular’s payout ratio is presently 36.90%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of LMAT. Sound Income Strategies LLC raised its holdings in LeMaitre Vascular by 425.6% in the first quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 183 shares during the last quarter. Cornerstone Planning Group LLC raised its holdings in LeMaitre Vascular by 534.0% in the third quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 283 shares during the last quarter. Catalyst Capital Advisors LLC purchased a new position in LeMaitre Vascular in the first quarter worth about $32,000. MAI Capital Management purchased a new position in LeMaitre Vascular in the third quarter worth about $38,000. Finally, First Horizon Corp purchased a new position in LeMaitre Vascular in the third quarter worth about $39,000. 84.64% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Wall Street Zen raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Weiss Ratings lowered shares of LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday. Zacks Research raised shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research note on Monday, April 13th. Roth Mkm reissued a “buy” rating and set a $117.00 price objective (up from $108.00) on shares of LeMaitre Vascular in a research note on Thursday, February 26th. Finally, Wells Fargo & Company boosted their price objective on shares of LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a research note on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $112.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.